Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma

NCT00087776 is registered in ClinicalTrials.gov with American Regent, Inc. as lead sponsor.

NCT NCT00087776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00087776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma
Lead sponsor
American Regent, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
December 6, 2002
Completion date
October 27, 2007
Enrollment
393 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma